ICON (ICLR) Saham Harga

ICON PLC, also known as ICON, is a well-established global provider of clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 in Dublin, Ireland, ICON has since expanded its operations worldwide, with offices in over 40 countries. The company offers various services, including clinical trial management, data management and analysis, regulatory support, and post-market surveillance. With a strong focus on innovation and expertise, ICON has successfully collaborated with numerous healthcare organizations to accelerate the development of innovative therapies and improve patient outcomes. Due to its vast experience and industry reputation, ICON PLC continues to be a trusted partner in advancing healthcare solutions globally.

The business model of ICON PLC is centered around providing clinical research services to pharmaceutical, biotechnology, and medical device companies. ICON offers a range of services including clinical trial management, data collection and analysis, regulatory consulting, and patient recruitment. They help their clients with the development and commercialization of new drugs and treatments by conducting clinical trials and ensuring regulatory compliance. With a strong focus on innovation and expertise in the field, ICON PLC has established itself as a trusted partner for the life sciences industry.

ICON PLC is primarily active in the pharmaceutical, biotechnology, and medical device industries.

ICON PLC, a leading clinical research organization, has achieved significant milestones throughout its history. The company's accomplishments include becoming a key player in the development and execution of clinical trials worldwide. ICON PLC has successfully expanded its global footprint, delivering exceptional services in over 100 countries. With a strong focus on innovation and technology, the company has pioneered industry-leading solutions to enhance clinical trial processes and improve patient outcomes. ICON PLC's dedication to excellence has resulted in numerous accolades and recognition within the pharmaceutical and biotechnology industries. By consistently delivering high-quality results and establishing strategic partnerships, ICON PLC has solidified its reputation as a trusted and influential player in the field of clinical research.

ICON PLC is primarily present in various countries and regions globally. With a strong international presence, the company operates in multiple key markets, including the United States, United Kingdom, Ireland, Europe, Asia-Pacific, and the Middle East. This global footprint enables ICON PLC to cater to clients worldwide and deliver its comprehensive range of professional services.

ICON PLC is a leading global provider of clinical research services to pharmaceutical, biotechnology, and medical device industries. ICON PLC is guided by a set of core values and corporate philosophy that focuses on innovation, integrity, collaboration, and excellence. The company's commitment to delivering high-quality research and development solutions, while maintaining ethical practices, has made it a trusted partner for successful clinical trials. With its dedication to advancing healthcare and improving patient outcomes, ICON PLC continues to be a respected and influential player in the industry.

Analis saat ini menetapkan target harga rata-rata 170,64 USD untuk saham ICON (median: 175,00 USD), yaitu -7,2 % terhadap harga terbaru. Konsensus didasarkan pada 24 peringkat analis.

ICON Target Harga Analis 2026

24 analis saat ini menilai saham ICON: 15 merekomendasikan beli, 8 tahan, dan 1 jual. Untuk 2026, analis memperkirakan ICON menghasilkan pendapatan 8,14 miliar USD dan laba per saham 11,48 USD.

ICON Target Harga Analis 2026

Dengan kurs saat ini, saham ICON diperdagangkan pada 163,97 EUR (183,91 USD).

Saham ICON (ICLR) tercatat di 4 bursa, termasuk: NASDAQ (ICLR), Frankfurt (IJF.F), München (IJF.MU), Düsseldorf (IJF.DU).

ICON plc is a leading global company in the field of clinical research and development of pharmaceuticals. It offers a wide range of services in clinical trials, consulting, strategy development, laboratory analysis, and data management. The company is divided into three main business areas: clinical development services, laboratory analysis, and data management. It works closely with its customers and partners to develop groundbreaking medications and treatments. ICON is known for its Enterprise Laboratory Information Management System (LIMS) and EDC solutions. It has a robust business model and is well-positioned for future growth.

Pendapatan diperkirakan dari ICON adalah 8,14 miliar USD. Angka ini didasarkan pada data keuangan terkini dan mencerminkan kinerja bisnis perusahaan.

Laba diperkirakan dari ICON adalah 878,86 Juta. USD. Laba bersih mencerminkan profitabilitas perusahaan setelah mengurangi semua biaya.

Rasio harga-terhadap-pendapatan (PER) ICON saat ini adalah 16,02. PER membandingkan harga saham saat ini dengan laba per saham dan membantu investor menilai valuasi saham ICON.

Rasio harga-terhadap-penjualan (PSR) ICON saat ini adalah 1,73. PSR membandingkan kapitalisasi pasar dengan pendapatan tahunan dan berfungsi sebagai metrik valuasi untuk saham ICON.

Skor Kualitas AlleAktien untuk ICON adalah 2/10.

ISIN dari ICON adalah IE0005711209. ISIN (International Securities Identification Number) adalah identifikasi unik global untuk sekuritas.

WKN dari ICON adalah 932242. WKN (Wertpapierkennnummer) adalah kode identifikasi sekuritas Jerman enam digit.

Ticker dari ICON adalah ICLR. Simbol ticker digunakan untuk memperdagangkan saham ICON di bursa saham.